Last Price
8.26
Today's Change
-0.015 (0.18%)
Day's Change
8.26 - 8.67
Trading Volume
408,193
Exchange: NASDAQ Global Market NASDAQ Global Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Dr. Barbara L. Weber M.D. Dr. Barbara L. Weber M.D.
Full Time Employees: 140 140
IPO Date: 2020-09-03 2020-09-03
CIK: 0001819133 0001819133
ISIN: US87583X1090 US87583X1090
CUSIP: 87583X109 87583X109
Beta: 0.85 0.85
Last Dividend: 0.00 0.00
Dcf Diff: 16.12 16.12
Dcf: -7.76 -7.76
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.